Kalaris Therapeutics will present Phase 1 study data of TH103 for retinal diseases at the Macula Society Meeting.
Quiver AI Summary
Kalaris Therapeutics, Inc. announced the presentation of clinical data from its Phase 1 study of TH103 at the upcoming 49th Annual Meeting of the Macula Society in San Diego, California, from February 25-28, 2026. TH103 is an investigational therapy developed by Dr. Napoleone Ferrara, known for enhancing VEGF inhibition and improving intraocular retention for treating neovascular age-related macular degeneration (AMD). The presentation will cover findings on safety, tolerability, pharmacokinetics, and initial efficacy following intravitreal administration in treatment-naive patients. The session will feature leading experts, with details including a speech by Dr. Dean Eliott of Harvard Medical School. Kalaris is focused on innovative therapies for retinal diseases, highlighting its commitment to addressing significant unmet medical needs.
Potential Positives
- Presentation of clinical data from Kalaris's Phase 1 study of TH103 at a prestigious meeting demonstrates a commitment to transparency and engagement with the scientific community.
- The investigational therapy TH103 targets retinal disease with innovative dual-targeting mechanisms, potentially positioning Kalaris as a leader in a niche market.
- Involvement of renowned expert Dr. Dean Eliott in the presentation underscores the credibility and significance of the research findings being shared.
Potential Negatives
- None
FAQ
What is TH103 and its significance?
TH103 is a novel investigational therapy for retinal diseases, designed for enhanced VEGF inhibition and increased intraocular retention.
Where will Kalaris present the clinical data for TH103?
Kalaris will present clinical data at the 49th Annual Meeting of the Macula Society in San Diego, California.
Who is the speaker presenting TH103 data?
The data will be presented by Dr. Dean Eliott, a leading ophthalmology expert from Harvard Medical School.
What are the key outcomes to be discussed in the presentation?
The presentation will cover safety, tolerability, pharmacokinetics, and early efficacy outcomes of TH103 in patients.
What is Kalaris Therapeutics' mission?
Kalaris is focused on developing and commercializing treatments for retinal diseases with significant unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KLRS Hedge Fund Activity
We have seen 15 institutional investors add shares of $KLRS stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCTAGON CAPITAL ADVISORS LP removed 360,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,080,800
- GILEAD SCIENCES, INC. removed 317,789 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,836,820
- WOODLINE PARTNERS LP added 241,102 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,393,569
- VANGUARD GROUP INC added 73,212 shares (+56.4%) to their portfolio in Q3 2025, for an estimated $423,165
- TANG CAPITAL MANAGEMENT LLC added 57,382 shares (+15.9%) to their portfolio in Q3 2025, for an estimated $331,667
- GEODE CAPITAL MANAGEMENT, LLC added 39,075 shares (+153.4%) to their portfolio in Q3 2025, for an estimated $225,853
- SIREN, L.L.C. added 35,678 shares (+12.6%) to their portfolio in Q3 2025, for an estimated $206,218
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KLRS Analyst Ratings
Wall Street analysts have issued reports on $KLRS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 11/03/2025
- Raymond James issued a "Strong Buy" rating on 09/03/2025
To track analyst ratings and price targets for $KLRS, check out Quiver Quantitative's $KLRS forecast page.
$KLRS Price Targets
Multiple analysts have issued price targets for $KLRS recently. We have seen 3 analysts offer price targets for $KLRS in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $19.0 on 12/23/2025
- Jonathan Wolleben from Citizens set a target price of $20.0 on 11/03/2025
- Chris Raymond from Raymond James set a target price of $23.0 on 09/03/2025
Full Release
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California.
TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal administration of TH103 in patients with treatment-naive neovascular age-related macular degeneration. The data will be presented during a scientific session attended by leading retinal specialists and clinical investigators.
Presentation Details:
- Title: First-in-Human Evaluation of TH103, a Dual-Targeting VEGF and HSPG Inhibitor: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD
- Speaker: Dean Eliott, MD, S.E. Gragoudas Professor of Ophthalmology, Harvard Medical School, Director Emeritus of Retina Service, Massachusetts Eye & Ear Infirmary
- Date: Thursday, February 26, 2026
- Time: 8:15 am PT
- Session: Neovascular AMD I: Clinical Trials
-
Location: Southpointe Ballroom, Hotel Del Coronado, San Diego, CA
The Macula Society Annual Meeting is a highly selective, invitation-only forum where internationally recognized retinal experts convene to present and critically evaluate emerging clinical data and novel therapeutic strategies in retinal vascular and macular disease.
About Kalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.
For more information, visit www.kalaristx.com .
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
[email protected]
[email protected]
